@@ 异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)为恶性疾病提供了一种全新的治疗策略并广泛应用于恶性疾病的治疗.通过移植治疗,其移植物抗白血病(graft-versus-leukemia,GVL)效应对恶性疾病的治疗及防止移植后疾病复发发挥着关键作用,但是随之而发生的移植物抗宿主病(graft-versus-host disease,GVHD)又是影响移植后生存的重要因素之一.本文通过对GVHD和GVL发生机制的深入认识,从而探索并制定GVHD和GVL的分离策略,使GVHD作用最小化和GVL效应最大化,从而为临床移植工作者提高移植的临床应用价值而提供更多更好的思路和方法.%Graft - versus - host disease ( GVHD ) is an important factor and has significant influence on survival after allogeneic hematopoietic stem cell transplantation ( allo - HSCT ). Graft - versus - leukemia ( GVL ) effect is a key factor that affects the treatment and recurrence after allo - HSCT. In order to increase the validity and safety on allo - HSCT in clinical application, the detailed mechanisms of GVHD and GVL are investigated, and the separation of GVL from GVHD in allo - HSCT, including early prediction and diagnosis of GVHD, modification of donor graft cells and drug intervention, is extensively studied.
展开▼
